Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans With Periodontal Disease

Vitamin D Deficiency Clinical Trial

— GumD  

Official title:

Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT02337257
• Other study ID #: Pro00001693
• Status: Unknown status
• Phase: Early Phase 1
• First received: December 11, 2014
• Last updated: January 8, 2015
• Start date: April 2014
• Est. completion date: December 2015

Study information

• Verified date: January 2015
• Source: Augusta University
• Contact: Yanbin Dong, PhD
• Phone: 706-721-5410
• Email: ydong[@]gru.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Poor vitamin D status is very common in African Americans. Periodontitis (gum disease) are shown to be related to theincreased risk of cardiometabolic diseases. Vitamin D is freely available and cheap supplement that has shown beneficialeffect in the immune system regulation and maintenance of the cardiovascular health. In this study The investigators hypothesize thatvitamin D supplementation for 16 weeks in African Americans with periodontitis will result in clinical improvement in theirgum health as well as their cardiometabolic risk profile

Description:

This is a double-blind placebo-controlled randomized clinical trial of vitamin D supplementation.

The eligible subjects will be assigned to a specific group by random assignment in one of the following two groups:

1. Group 1 who will receive placebo.

2. Group 2 who will receive 4,000 IU vitamin D.

Both groups will receive either the placebo pills or vitamin D supplementation everyday for 16 weeks. At visit 1: a fasting morning urine sample will be collected. Height, weight, hip and waist circumferences will be measured. Automatic and manual blood pressures will be measured in sitting position. Approximately 80 ml of venous blood will be collected. Arterial stiffness will be assessed non-invasively by the SphygmoCor device. This device also measures the central (aortic) BP and simultaneously measures pulse wave velocity (PWV). A bottle of 30 capsules containing either vitamin D or placebo will be given to the subjects and will be asked to take one capsule every day for next month till the second visit. A questionnaire to assess the dietary habits, tobacco use, sun exposure, physical activity, socio-economic status and family health history will be given to the subject. At the dental clinic, full mouth clinical measurements (periodontal probing) will be performed. A plaque sample will be taken and a gum biopsy will be taken to examine the dendritic cells. Also, a saliva sample will be collected.

At visit 2: one month later, the supplements will be replenished, compliance will be assessed, and subjects will be examined for any potential side effects.

At visit 3: at 8-week follow up, anthropometric measures, blood samples as well as BP and PWV will be measured and the subject will be assessed for clinical improvement in the periodontitis. All the subjects, irrespective of their group assignment will undergo intensive scaling and root planing (S&RP). The supplements will be replenished, compliance will be assessed, and subjects will be examined for any potential side effects.

Another fasting blood draw, BP measurement and PWV will be performed approximately 24 hours after the S&RP. Also, the investigators will collect saliva sample during this visit.

At visit 4: at 12-week follow up, the procedure in this visit are similar to the visit 2.

At visit 5: at 16-week follow up, a post-test evaluation of vitamin D status, cardiovascular phenotypes and periodontitis will be done at the end of the study.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 24
• Est. completion date: December 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. You are African American

2. You have generalized chronic moderate to severe gum disease (periodontitis)

3. Your age is between 18-60 years.

4. You are not taking any vitamin, mineral or herbal supplements

5. If you are a female, you are not pregnant

Exclusion Criteria:

• Not meeting any of the above

Related Conditions & MeSH terms

• Gingival Diseases
• Periodontal Disease
• Periodontal Diseases
• Vitamin D Deficiency

Intervention

Drug:
• Cholecalciferol
subjects will receive one pill per day which contains 4000 IU/d for 16 weeks
• Placebo
subjects will receive placebo one pill per day for 16 weeks

Locations

Country	Name	City	State
United States	Georgia Prevention Institute	Augusta	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
Augusta University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Periodontal Disease Activity	Periodontal disease activity will be measured using standard periodontal disease measures of pocket depth, blood on probing, periodontal inflamed surface area, plaque scores, bone loss, and clinical attachment loss	Baseline, 8 Weeks, 16 weeks.
Primary	Change in Cardiometabolic Risk Factors	Cardiometabolic risk factors will be measured by pulse wave velocity, central and peripheral blood pressure and glycated hemoglobin (A1C)	Baseline, 8 Weeks, 24hrs post-Scaling and Root planing, 16 weeks.
Secondary	Change in Blood Myeloid Dendritic Cells	Relative gene expression (transcripts) in blood myeloid dendritic cells (mDCs) by polymerase chain reaction (PCR) array, validated by protein, of markers of DC homeostasis and atherogenesis.	Baseline, 8 Weeks, 24hrs post-Scaling and Root planing, 16 weeks.